Pediatric Myocarditis: What Have We Learnt So Far?

被引:8
|
作者
Pomiato, Elettra [1 ]
Perrone, Marco Alfonso [1 ]
Palmieri, Rosalinda [1 ]
Gagliardi, Maria Giulia [1 ]
机构
[1] Bambino Gesu Pediat Hosp, Dept Pediat Cardiol & Cardiac Surg, IRCCS, I-00165 Rome, Italy
关键词
myocarditis; children; endomyocardial biopsy; inflammatory cardiomyopathy; immune system; GIANT-CELL MYOCARDITIS; CARDIOVASCULAR MAGNETIC-RESONANCE; ENDOMYOCARDIAL BIOPSY; FOLLOW-UP; DILATED CARDIOMYOPATHY; UNITED-STATES; IMMUNOSUPPRESSIVE THERAPY; CLINICAL PRESENTATION; CIRCULATORY SUPPORT; REPAIRED TETRALOGY;
D O I
10.3390/jcdd9050143
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myocarditis is an inflammatory disease of the myocardium that is troublesome to diagnose and manage, especially in children. Since the introduction of endomyocardial biopsy (EMB), new diagnostic tools have provided useful data. Especially when enhanced with immunohistochemistry and polymerase chain reaction (PCR) studies, EMB remains the gold standard for the diagnosis. Notably, cardiac magnetic resonance (MRI) is a non-invasive tool that can confirm the diagnosis and has a particular usefulness during the follow-up. The causes of myocarditis are heterogeneous (mostly viral in children). The course and outcome of the illness in the pediatric population represent a complex interaction between etiologic agents and the immune system, which is still not fully understood. The clinical presentation and course of myocarditis vary widely from paucisymptomatic illness to acute heart failure refractory to therapy, arrhythmias, angina-like presentation and sudden cardiac death. In this setting, cardiac biomarkers (i.e., troponins and BNP), although unspecific, can be used to support the diagnosis. Finally, the efficacy of therapeutic strategies is controversial and not confirmed by clinical trials. In this review, we summarized the milestones in diagnosis and provided an overview of the therapeutic options for myocarditis in children.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Clinical trials for neuroregenerative therapies for spinal cord injury: what have we learnt so far?
    Wong, Raymond
    Hejrati, Nader
    Fehlings, Michael G. G.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (06) : 487 - 499
  • [32] Alcohol consumption during COVID-19 pandemic: What have we learnt so far?
    Nogueira, V.
    Mendes, M.
    Pereira, I.
    Teixeira, J.
    [J]. EUROPEAN PSYCHIATRY, 2021, 64 : S103 - S103
  • [33] Two years of COVID-19 in the MS community: What have we learnt so far?
    Zabalza, Ana
    Thompson, Alan J.
    Montalban, Xavier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (07) : 1005 - 1008
  • [34] The history of number words in the world's languages-what have we learnt so far?
    Calude, Andreea S.
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2021, 376 (1824)
  • [35] Fukushima - what have we learned so far?
    Kidd, Steve
    [J]. NUCLEAR ENGINEERING INTERNATIONAL, 2011, 56 (685): : 12 - 13
  • [36] Brexit: What Have We Learned So Far?
    Besch, Sophia
    Black, James
    [J]. SURVIVAL, 2016, 58 (05) : 59 - 67
  • [37] METROPTIC - WHAT WE HAVE DONE SO FAR
    ELLISON, M
    [J]. JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION, 1981, 52 (06) : 483 - 484
  • [38] Acrylamide: What we have learned so far
    Coughlin, JR
    [J]. FOOD TECHNOLOGY, 2003, 57 (02) : 100 - 100
  • [39] Levosimendan: What Have We Learned So Far?
    Giulia Villa
    Guido Tavazzi
    Fabio Guarracino
    Fabio Sangalli
    [J]. Current Anesthesiology Reports, 2019, 9 : 234 - 241
  • [40] Levosimendan: What Have We Learned So Far?
    Villa, Giulia
    Tavazzi, Guido
    Guarracino, Fabio
    Sangalli, Fabio
    [J]. CURRENT ANESTHESIOLOGY REPORTS, 2019, 9 (03) : 234 - 241